Trial Profile
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Shanghai Henlius Biotech
- 22 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Jun 2015 New trial record